For decades, NORD has pursued federal and state policies to improve the lives of Americans impacted by rare diseases. This page is updated daily to provide timely information on our policy efforts. Please contact [email protected] if you have questions or need additional information.
NORD Rare Disease Centers of Excellence Letter to HHS on Termination of ACHDNC
Published: Apr 6, 2025
Tagged in: Access to Diagnostics
Newborn Screening
NORD CEO Statement on the Termination of the Advisory Committee on Heritable Disorders in Newborns and Children
Published: Apr 4, 2025
Tagged in: Access to Diagnostics
Newborn Screening
Public Health
NORD joins statement urging CFPB to protect consumers’ medical information
Published: Aug 12, 2024
NORD joins statement urging CMS to reduce barriers to access in Iowa’s Medicaid program
Published: Aug 11, 2024
Tagged in: Access to Affordable, Adequate Coverage
Medicaid Section 1115 Waivers
Medicare, Medicaid, and Private Health Insurance Coverage
NORD submits comments in response to RFI on Cures 2.0
Published: Aug 2, 2024
Tagged in: Access to Affordable Medicines
Access to Affordable, Adequate Coverage
Access to Diagnostics
Access to Innovative Medicines and Therapies
Advancing Rare Disease Research and Regulatory Science
FDA’s Accelerated Approval Pathway
Telehealth
NORD Signs on to Letter of Support for the Innovation in Pediatric Drugs Act of 2024 (S. 4905)
Published: Aug 2, 2024
Tagged in: Access to Innovative Medicines and Therapies
Access to Pediatric Therapies
NORD joins leading patient groups in supporting New York’s Medicaid Redesign Team Waiver
Published: Jul 24, 2024
Tagged in: Access to Affordable, Adequate Coverage
Medicare, Medicaid, and Private Health Insurance Coverage
34 Patient Organizations Join NORD in Urging California Senate Appropriations to Support an RDAC in CA
Published: Jul 19, 2024
Tagged in: Rare Disease Advisory Councils (RDACs)
NORD Urges the California State Senate to Support AB2613 (Zbur) to Create a Rare Disease Advisory Council
Published: Jul 19, 2024
Tagged in: Rare Disease Advisory Councils (RDACs)
NORD joins statement supporting Maryland’s 1332 waiver request
Published: Jul 9, 2024
Tagged in: Access to Affordable, Adequate Coverage
Affordable Care Act
Section 1332 Waivers
NORD Submits Comments to CMS on Medicare Drug Price Negotiation Draft Guidance
Published: Jul 2, 2024
Tagged in: Access to Affordable, Adequate Coverage
Federal Drug Pricing Legislation in the 116th Congress
Medicare, Medicaid, and Private Health Insurance Coverage
Out of Pocket Prescription Drug Costs
NORD Sends a Letter of Support to Members the House Energy and Commerce Committee to Vote Yes to Advance Amendment in the Nature of a Substitute to H.R. 3433, Give Kids a Chance Act, which includes key provisions of H.R.7384, Creating Hope Reauthorization Act, H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act, and H.R. 6664, Innovation for Pediatric Drugs Act
Published: Jun 26, 2024
Tagged in: Access to Affordable Medicines
Access to Affordable, Adequate Coverage
Access to Innovative Medicines and Therapies
NORD Leads Nearly 200 Patient Advocacy Organizations In a Letter of Support to Reauthorize Rare Disease Pediatric Review Voucher (PRV) Program
Published: Jun 24, 2024
Tagged in: Access to Innovative Medicines and Therapies
NORD Responds to Letter of False Accusations Sent to Our Patient Advocacy Members
Published: Jun 20, 2024
Tagged in: Access to Affordable Medicines
Access to Affordable, Adequate Coverage
NORD Submits Comments on Docket No. FDA-2023-D-5470 for “Real-World Evidence: Considerations Regarding Non- Interventional Studies for Drug and Biological Products”
Published: Jun 17, 2024
Tagged in: Advancing Rare Disease Research and Regulatory Science
NORD Supports NCATS Alliance in Recommendation that Congress Allocate $51.303B for the NIH and $1.194B for the NCATS for Fiscal Year 2025 Appropriations
Published: Jun 13, 2024
NORD Joins 24 Patient and Provider Groups in a Statement Regarding the Supreme Court’s Decision in Alliance for Hippocratic Medicine v. FDA
Published: Jun 13, 2024
Tagged in: Access to Innovative Medicines and Therapies
Protecting FDA Standards for Safe and Effective Drugs
NORD Signs on to Letter Offering Recommendations for Patient Priorities for the 2026 Notice of Benefit and Payment Parameters
Published: Jun 7, 2024
Tagged in: Access to Affordable Medicines
Access to Affordable, Adequate Coverage
Affordable Care Act
NORD & 16 Patient Organizations Ask Speaker Carl Heastie and Leader Andrea Stewart-Cousins for a Permanent NY RDAC (A10292-A/S9724)
Published: May 31, 2024
Tagged in: Rare Disease Advisory Councils (RDACs)
NORD joins 122 other organizations in advocating for increased funding for Congressionally Directed Medical Research Programs (CDMRP)
Published: May 30, 2024
Tagged in: Advancing Rare Disease Research and Regulatory Science
NORD Supports Pennsylvania House Bill 1754 Providing Coverage for Biomarker Testing
Published: May 29, 2024
Tagged in: Access to Diagnostics
Access to Innovative Medicines and Therapies
Gene Therapies
Genetic Testing
NORD joins leading patient groups in urging Congress to require CMS to provide annual updates on the Medicare Prescription Payment Plan (MP3)
Published: May 24, 2024
Tagged in: Access to Affordable, Adequate Coverage
NORD Issues Letter of Support for A10292 (Paulin) – Creating a Permanent RDAC in New York State
Published: May 17, 2024
Tagged in: Rare Disease Advisory Councils (RDACs)
NORD Issues Letter of Support for North Carolina Bill HB681 Joining the Interstate Medical Licensure Compact (IMLC)
Published: May 14, 2024
Tagged in: Telehealth
NORD joins leading patient groups in urging CMS to approve Colorado’s Demonstration Amendment extending continuous eligibility to children on Medicaid
Published: May 13, 2024
Tagged in: Access to Affordable, Adequate Coverage
Medicare, Medicaid, and Private Health Insurance Coverage
NORD Urges Congress to Reauthorize the Rare Pediatric Disease Priority Review Voucher Program: H.R. 7384, the Creating Hope Reauthorization Act
Published: May 9, 2024
Tagged in: Advancing Rare Disease Research and Regulatory Science
NORD Joins a Letter of Support on Innovation in Pediatric Drugs Act of 2023 (H.R. 6664)
Published: May 8, 2024
Tagged in: Access to Innovative Medicines and Therapies
Advancing Rare Disease Research and Regulatory Science
NORD joins letter of support urging funding for the Pediatric Device Consortia Grant Program
Published: May 6, 2024
Tagged in: Access to Innovative Medicines and Therapies
Advancing Rare Disease Research and Regulatory Science
NORD joins letter supporting H.R. 5397, a bill to increase access to home infusion for Medicare patients
Published: May 3, 2024
Tagged in: Access to Affordable Medicines
Access to Affordable, Adequate Coverage
Medicare, Medicaid, and Private Health Insurance Coverage
NORD Supports H7363 (Kennedy)/S2390 (Lawson) – Establishes a Rare Disease Advisory Council in the State of Rhode Island
Published: Apr 30, 2024
Tagged in: Rare Disease Advisory Councils (RDACs)
NORD joins leading patient groups in submitting comments to CMS on M3P model documents
Published: Apr 29, 2024
Tagged in: Access to Affordable, Adequate Coverage
Medicare, Medicaid, and Private Health Insurance Coverage
Out of Pocket Prescription Drug Costs
NORD Sends Comments Regarding Colorado SB24-203
Published: Apr 26, 2024
Tagged in: Out of Pocket Prescription Drug Costs
Rare Disease Advisory Councils (RDACs)
NORD Joins 32 Patient Organizations in Applauding the Release of Section 1557 of the Affordable Care Act Rule to Protect All Patients from Discrimination When Accessing Health Care
Published: Apr 26, 2024
Tagged in: Access to Affordable, Adequate Coverage
Affordable Care Act
NORD joins leading patient groups in providing comments to CMS on Florida’s 1115 CHIP eligibility extension
Published: Apr 24, 2024
Tagged in: Access to Affordable, Adequate Coverage
Medicare, Medicaid, and Private Health Insurance Coverage
NORD Joins the All Copays Count Coalition in Writing to the Insurance Commissioners of all 50 States Encouraging them to Enforce the 2020 NBPP Provision Restricting the Use of Copay Accumulator Adjusters
Published: Apr 19, 2024
Tagged in: Copay Assistance
NORD Responds to Proposed Amendments Offered by Health Plans to Step Therapy Provisions of Vermont H.766 (Black)
Published: Apr 18, 2024
Tagged in: Access to Affordable Medicines
Access to Affordable, Adequate Coverage
Access to Innovative Medicines and Therapies
Utilization Management
NORD submits comments to Colorado State, Veterans, and Military Affairs Committee on SB24-203
Published: Apr 17, 2024
NORD & Patient Organizations Ask Mississippi Governor Tate Reeves to Sign SB2156 MS RDAC Bill Into Law
Published: Apr 4, 2024
Tagged in: Rare Disease Advisory Councils (RDACs)
NORD and 34 Patient Organizations Celebrate Biden Administration’s Rule to Protect Patients from Short-Term Health Plans
Published: Mar 28, 2024
Tagged in: Access to Affordable Medicines
Access to Affordable, Adequate Coverage
NORD Sends Letter of Support to Vermont Senate Health for H.766 Relating to Step Therapy Reforms
Published: Mar 27, 2024
Tagged in: Access to Affordable Medicines
Access to Affordable, Adequate Coverage
Access to Innovative Medicines and Therapies
Utilization Management
NORD & 22 Patient Organizations Issue Letter of Support & Recommendations for MS RDAC Bills HB616/SB2156
Published: Mar 25, 2024
Tagged in: Rare Disease Advisory Councils (RDACs)
NORD Submits Statement for the Record on the LDT Hearing
Published: Mar 21, 2024
Tagged in: Access to Innovative Medicines and Therapies
Advancing Rare Disease Research and Regulatory Science
NORD Signs On To Letter Urging Congress to Swiftly Pass Pharmacy Benefit Manager (PBM) Reforms That Ensure Patient Access to More Affordable Healthcare
Published: Mar 19, 2024
Tagged in: Access to Affordable Medicines
Access to Affordable, Adequate Coverage
NORD Issues Letter of Support for Rhode Island S2611/H7822 Regarding Step Therapy Protocols
Published: Mar 18, 2024
Tagged in: Access to Affordable Medicines
Access to Affordable, Adequate Coverage
Access to Innovative Medicines and Therapies
Utilization Management
NORD joins coalition of leading patient organizations in submitting comments to CMS on the Medicare Prescription Payment Plan (MPPP) Part 2 Draft Guidance
Published: Mar 15, 2024
NORD submits comments to CMS in response to the Medicare Prescription Payment Plan (MPPP) Draft Guidance – Part Two
Published: Mar 15, 2024
Tagged in: Access to Affordable Medicines
Access to Affordable, Adequate Coverage
Medicare, Medicaid, and Private Health Insurance Coverage
Out of Pocket Prescription Drug Costs
NORD Signs On to A Letter to The Committee on Education and the Workforce Request for Information on Employer-Sponsored Insurance and Employee Retirement Income Security Act (ERISA)
Published: Mar 15, 2024
Tagged in: Access to Affordable Medicines
Access to Affordable, Adequate Coverage
NORD with the Safe Step Act Ad Hoc Coalition Submit Comments for the Committee’s RFI On The Employee Retirement Income Security Act (ERISA) with Recommendations to Reform Step Therapy and Mark Up Safe Step Act (H.R. 2630)
Published: Mar 15, 2024
Tagged in: Access to Affordable Medicines
Access to Affordable, Adequate Coverage
Access to Innovative Medicines and Therapies
NORD Issues Letter of Support for New Jersey A1825 Regarding Step Therapy Protocols
Published: Mar 13, 2024
Tagged in: Access to Affordable Medicines
Access to Affordable, Adequate Coverage
Access to Innovative Medicines and Therapies
Utilization Management
NORD joins leading patient organizations in submitting comments to CMS on Pennsylvania 1115 waiver
Published: Mar 13, 2024
NORD Joins Patient Organizations in Support of New Jersey A1825 Establishing Step Therapy Protocols
Published: Mar 13, 2024
Tagged in: Access to Affordable Medicines
Access to Affordable, Adequate Coverage
Out of Pocket Prescription Drug Costs
Utilization Management
NORD Sends Letter of Support to the Vermont House for Provisions of Vermont H.766 Relating to Step Therapy Requirements
Published: Mar 12, 2024
Tagged in: Access to Affordable Medicines
Access to Affordable, Adequate Coverage
Access to Innovative Medicines and Therapies